<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02017418</url>
  </required_header>
  <id_info>
    <org_study_id>2012-10531</org_study_id>
    <nct_id>NCT02017418</nct_id>
  </id_info>
  <brief_title>The Effects of a Zeaxanthin Intervention on Visuomotor Function</brief_title>
  <official_title>The Effects of a Zeaxanthin Intervention on Visuomotor Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Georgia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZeaVision, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Georgia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to test whether two zeaxanthin formulations (supplements containing&#xD;
      different nutritional compounds with zeaxanthin and omega fatty acids being the primary&#xD;
      ingredients of interest) influenced visual motor function. Visual motor function refers to&#xD;
      the processing speed of the visual system and how individuals respond behavioral to visual&#xD;
      stimuli (e.g., reaction time).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed to test whether two zeaxanthin formulations (supplements containing&#xD;
      different nutritional compounds with zeaxanthin and omega fatty acids being the primary&#xD;
      ingredients of interest) influenced visual motor function. Visual motor function refers to&#xD;
      the processing speed of the visual system and how individuals respond behavioral to visual&#xD;
      stimuli (e.g., reaction time).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macular pigment optical density</measure>
    <time_frame>one year</time_frame>
    <description>Increases in the amount of macular pigment measured in optical density units</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fixed reaction time</measure>
    <time_frame>one year</time_frame>
    <description>reaction time to a stimulus fixed in space</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>variable reaction time</measure>
    <time_frame>12-months</time_frame>
    <description>reaction time to a stimulus with a position that varies in space</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coincidence anticipation</measure>
    <time_frame>12-months</time_frame>
    <description>button press when a light stimulus of varying speeds reaches a specific point in a linear light array</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Behavior and Behavior Mechanisms</condition>
  <arm_group>
    <arm_group_label>zeaxanthin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo zeaxanthin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combinatory supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo combinatory supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>zeaxanthin</intervention_name>
    <description>softgel</description>
    <arm_group_label>zeaxanthin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>combinatory supplement</intervention_name>
    <description>softgel</description>
    <arm_group_label>combinatory supplement</arm_group_label>
    <other_name>zeaxanthin + lutein + DHA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: ≥18 and ≤ 40 years&#xD;
&#xD;
          -  BMI: ≥ 20 and ≤ 30 kg/m2&#xD;
&#xD;
          -  No anticipated changes in dieting habits (as relevant to the intake of xanthophylls&#xD;
             and fats/oils).&#xD;
&#xD;
          -  No anticipated surgical procedures.&#xD;
&#xD;
          -  Willingness and ability to give written informed consent and willingness and ability&#xD;
             to comply with the study requirements.&#xD;
&#xD;
          -  Corrected visual acuity (ETDRS): better than 20/60 in the eye selected for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Current or history of relevant ocular diseases (such as AMD) or other conditions e.g.,&#xD;
             lipid disorders.&#xD;
&#xD;
          -  Inability to reliably perform macular pigment optical density measurements by&#xD;
             &quot;Heterochromatic Flicker Photometry&quot; or any of the other ophthalmic tests of the&#xD;
             study.&#xD;
&#xD;
          -  Any condition likely to interfere with normal gastro-intestinal absorption of&#xD;
             xanthophylls (e.g., digestive disorders: inflammatory bowel disease, ulcerative&#xD;
             colitis, Crohn's, irritable bowel, etc. or lipid disorders including conditions such&#xD;
             as hypercholesterolemia)&#xD;
&#xD;
          -  Current use of xanthophyll containing supplements or use of xanthophyll containing&#xD;
             supplements in the past 6 months (but excluding multivitamins containing lutein or&#xD;
             zeaxanthin at low potency).&#xD;
&#xD;
          -  Participation in any other study during last 1 month before study initiation.&#xD;
&#xD;
          -  Known hypersensitivity or allergy to xanthophylls.&#xD;
&#xD;
          -  Regular intake of medications or supplements, which the principal investigator deems&#xD;
             likely to confound the study outcomes. These include diabetes medication and statins&#xD;
             or any other drug/supplement to modulate cholesterol or fat digestion/absorption.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Billy R Hammond, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Georgia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychology, UGA</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Georgia</investigator_affiliation>
    <investigator_full_name>Billy R. Hammond</investigator_full_name>
    <investigator_title>Professor and Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>zeaxanthin</keyword>
  <keyword>visual function</keyword>
  <keyword>reaction time</keyword>
  <keyword>processing speed</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

